• 1. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 2. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 3. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 4. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 5. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Comprehensive Overview of N-(trans-4-Methoxycyclohexyl)carbamic Acid 1,1-Dimethylethyl Ester (CAS No. 760958-17-6)

N-(trans-4-Methoxycyclohexyl)carbamic Acid 1,1-Dimethylethyl Ester (CAS No. 760958-17-6) is a specialized organic compound that has garnered significant attention in pharmaceutical and chemical research. This ester derivative, characterized by its trans-4-methoxycyclohexyl and tert-butyl moieties, is widely utilized in the synthesis of bioactive molecules. Its unique structural features make it a valuable intermediate in drug discovery, particularly in the development of kinase inhibitors and central nervous system (CNS) therapeutics.

The compound's carbamate functionality and methoxycyclohexyl group contribute to its stability and solubility, which are critical for optimizing pharmacokinetic properties. Researchers are increasingly exploring its potential in targeted drug delivery systems, a hot topic in modern medicine. With the rise of personalized medicine and AI-driven drug design, CAS No. 760958-17-6 has become a subject of interest for computational chemists and medicinal chemists alike.

In recent years, the demand for high-purity intermediates like N-(trans-4-Methoxycyclohexyl)carbamic Acid 1,1-Dimethylethyl Ester has surged due to advancements in high-throughput screening (HTS) and combinatorial chemistry. Its role in the synthesis of proteolysis-targeting chimeras (PROTACs) has also been highlighted, aligning with the growing focus on degradation-based therapeutics. This compound's versatility underscores its importance in cutting-edge research.

From a synthetic perspective, CAS No. 760958-17-6 is often prepared via carbamate coupling reactions involving trans-4-methoxycyclohexylamine and di-tert-butyl dicarbonate. The reaction conditions are meticulously optimized to ensure high yield and purity, which are essential for downstream applications. Analytical techniques such as HPLC, NMR, and mass spectrometry are routinely employed to validate the compound's identity and quality.

The compound's relevance extends to green chemistry initiatives, where researchers aim to minimize waste and improve sustainability. Its efficient synthesis and potential for catalytic recycling align with the principles of environmentally friendly chemical processes. As the pharmaceutical industry shifts toward sustainable practices, N-(trans-4-Methoxycyclohexyl)carbamic Acid 1,1-Dimethylethyl Ester exemplifies how intermediates can contribute to greener drug development.

In conclusion, N-(trans-4-Methoxycyclohexyl)carbamic Acid 1,1-Dimethylethyl Ester (CAS No. 760958-17-6) is a pivotal compound in modern chemical and pharmaceutical research. Its applications span drug discovery, bioconjugation, and material science, making it a versatile tool for scientists. As the field evolves, this compound will likely play an even greater role in addressing challenges related to drug efficacy and sustainability.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)